Ann: FY23 Results Presentation, page-12

The CEO said that BARDA trial outcomes will change the trajectory of sales I.e., steepen the growth curve. But it won’t just be as a result of sales to BARDA, large as that might be, but the FDA approval will have a broader sales effect in the US market.
DW emphasised that the co has an excellent working relationship with BARDA and the FDA.
The approval to extend recruitment beyond the US to include India is one indicator of this.
Of course the inclusion of subjects in India does double duty in that it would be welcomed by Indian authorities and clinicians.

As to the SynPath trial, I think it a good thing that they are prepared to alter the study protocol in light of finding out that the clinicians involved don’t fully appreciate the mechanism of action of NovoSorb. I’m impressed by the CEO.